Columbia Laboratories Acquires Molecular Profiles
Columbia Laboratories acquires Molecular Profiles in multimillion-dollar deal.
Columbia Laboratories has acquired Molecular Profiles, a UK-based pharmaceutical development services company, for approximately $25 million.
This acquisition was unanimously approved by the boards of directors of both companies and received the approval of Molecular Profiles’ shareholders. No further approvals are anticipated to be required.
According to the company, Molecular Profiles’ recorded approximately $9 million in revenues for its fiscal year ended July 31, 2013.
Source: Columbia Laboratories
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
